Hypericum perforatum L.

Tue, 17 May 2005 11:18:48 +0200


  • Anderson R., Flynn N., Jian S., Samuels S., Perkins C., Enders S.: “Testing is not enough: do IDU know their serostatus?” Abstract, Proceedings of VIII International Conference on AIDS, Amsterdam, UK Dept of Health Press Release (2000/01210) 1 March 2000.
  • Bailey D.G., Malcolm J., Arnold O., Spence J.D.: “Grapefruit Juice-Drug Interactions”, Br J Clin Pharmacol, 46(2):101-10, 1998.
  • Baureithel K.H., Buter K.B., Engesser A. et al.: “Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum”, Pharm Acta Helv, 72(3):153-7, 1997.
  • Bergman (1993) citato in Linde , et al. (1996)
  • Bernd A., Simon S., Ramirez Bosca A. et al.: “Phototoxic effects of Hypericum extract in cultures of human keratinocytes compared with those of psoralen”, Photochem Photobiol, 69(2):218-21, 1999.
  • Bianchi A., Adamoli R., Durante A., Saibene A.: Piante Medicinali e AIDS, Milano, Ed. Tecniche Nuove, 1997.
  • Bladt S., Wagner H.: “Inhibition of MAO by fractions and constituents of hypericum extract”, J Geriatr Psychiatry Neurol, 7 Suppl 1:S57-59, 1994.
  • Bloomfield, H.: Hypericum and Depression, Prelude, 1996.
  • Blumenthal M., Busse W.R. et al.: The Complete German Commission E Monographs -Therapeutic Guide to Herbal Medicines, Austin Tex. American Botanical Council, 1998.
  • Bombardelli E., Morazzoni P.: “Hypericum perforatum”, Fitoterapia, LXVI (1): 43-68, 1995.
  • Breinholt V., Lauridsen S.T., Dragstead L.O.: “Differential effects of dietary flavonoids in drug metabolizing and antioxidant enzymes in female rat”, Xenobiotica, Vol. 29, No 12, 1227-40, 1999.
  • British Herbal Pharmacopoeia (1983), p.116. British Herbal Medicine Association, Bournemouth UK.
  • Brochmoller J., Rheum T., Bauer S., Kerb R., Hubner W.D., Roots I.: “Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans”, Pharmacopsychiatry, 30 (suppl 2), 94-101, 1997.
  • Buchner S., Buchn: Repert, 1830; 34:217
  • Chan W.K., Nguyen L.T., Miller V.P., Harris R.Z.: “Mechanism based on inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine”, Life Sciences, 62, (10), 135-42, 1998.
  • Chatterjee S.S., Bhattacharya S.K., Wonnemann M. et al.: “Hyperforin as a possible antidepressant component of Hypericum extracts”, Life Sciences, 63(6):499-510, 1998b.
  • Chatterjee SS. et al. : “Antidepressant activity of Hypericum and hyperforin”, J Pharmacophsychiatrics. 31(suppl 1): 7-15, 1998a.
  • Conseil G., Baubichon-Cortay H., Dayan G., Jault J.M., Barron D., Di Pietro A.: “Flavonoids: a class of modulators with bifunctional interactions at vicinal AT-and seroid-binding sites on a mouse P-glycoprotein”, Proc Natl Acad Sc USA, 95, 9831-6, 1998.
  • Cooper WC., James J.: “An observational study of the safety and efficacy of hypericin in HIV+ subjects”, VI Int Conf AIDS, San Francisco, 6(2): 369, 1990 (abstract 2063).
  • Cott J.M.: “Is St John's Wort an effective anti-depressant?”, J Nerv Ment Dis, 186(8): 500-1, 1998.
  • Cott, J., Misra, L.: “Medicinal plants: A potencial source for new psychotherapeutic drugs”, in: S. Kamba, E. Richelson (eds.) New drug development from herbal medicine in neuropsychopharmacology New York, NY: Brunner/Mazel Inc, 1997.
  • Cracchiolo, C. Pharmacology of St. John’s wort: Botanical and Chemical Aspects. The Scientific Review of Alternative Medicine, 1998, 2 (1): 29–35
  • Czekalla J. et al.: “The effect of Hypericum extract on cardiac conduction”, J Pharmacopsychiat 30:86-8, 1997.
  • Degar et al. (1992): citato in Bianchi et al. (1997).
  • Denke A., Schneider W., Elstner E.F.: “Biochemical activities of extracts from Hypericum perforatum L. 2nd Communication: inhibition of metenkephaline- and tyrosine-dimerization”, Arzneimittelforschung, 49(2):109-14, 1999.
  • Djordjevic D., Nikolic J., Stefanovic V.: “Ethanol interactions with other cytochrome P450 substrates, including drugs, xenobiotics and carcinogens”, Patho Biol (Paris), Vol. 46 (10) 760-70, 1998.
  • EHPA, sito ufficiale.
  • Ellingwood, Finley: Reprint of American Materia Medica, 1917 Portland, Oregon: Eclectic Medical Publications, 1983.
  • Ernst E., Rand J.I., Barnes J., Stevinson C.: “Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.)”, Eur J Clin Pharmacol, 54(8):589-94, 1998.
  • Ernst E.: “[St John's wort as an antidepressive therapy] Johanniskraut zur antidepressiven Therapie”, Fortschr Med, 113(25):354-5, 1995.
  • Ernst E.: “Second thoughts about the safety of St. John's wort”, Lancet, Vol. 345, 2014, 1999.
  • Firenzuoli F., Luigi G.: “Letter”, J Alt and Comp Med, 5, (5), 397-8, 1999.
  • Fugh-Berman A., Cott M.: “Dietary Supplements and Natural Products as Psychotherapeutic Agents”, Psychosomatic Medicine, 61:712-28, 1999.
  • Furner V., Bek M., Gold J.: “A phase I/II unblinded dose ranging study of hypericin in HIV positive subjects”, VII Int Conf AIDS Florence 7(2): 199 (abstract WB 2071), 1991.
  • Garret B.J. et al.: “Consumption of poisonous plants (Senecio jacobaea, Symphytum officinale, Pteridium aquilinum, Hypericum perforatum) by rats: Chronic toxicity, mineral metabolism and hepatic drug-metabolizing enzymes”, Toxicology Letters, 10:183-388, 1982.
  • Geise A.C.: “Hypericism”, Photochem Photobiol Rev, 5:229-55, 1980.
  • Glue P. and Clement R.P.: “Cytochrome P450 Enzymes and Drug Metabolism”, Cell Molec Neurobiol, Vol. 19, No 3, 1999.
  • Golsch S., Vocks E., Rakoski J.: “Reversible increase in photosensitivity to UV-B caused by St. John's wort extract”, Hautartz, 48, 249, 1997.
  • Gordon J.: “SSRIs and St John's wort, possible toxicity?”, Am Fam Physician, 62, 31, 1998.
  • Grunwald, Hall, Riggins, Rister: (eds) Monografie della Commissione E, 1997.
  • Guengerich F.P., Shimada T., Yun C.H., Yamazaki H., Raney K.D., Their R., Coles B., Harris T.M.: “Interactions of ingested food, beverage and tobacco components involving human cytochrome P450 1A, 2A6, 2E1 and 3A4 enzymes”, Environ Health Persp, 102, (S9), 49-53, 1994.
  • Hansgen KD., Vesper J., Ploch M.: “Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160”, Nervenheilkunde 12:281-4, 1993.
  • Harrer G. and Schulz V.: “Clinical investigation of the antidepressant effectiveness of hypericum”, J Geriatr Psychiatry Neurol, 7 Suppl 1:S6-8, 1994a.
  • Harrer G., Hubner WD., Podzuweit H.: “Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: A multicenter double-blind study”, J Geriatr Psychiatry Neurol 7 Suppl 1: S24-28, 1994b.
  • Holtje HD. and Walper, A.: “Molecular modeling of the antidepressive mechanism of Hypericum ingredients”, Nervenheilkunde; 12:339-40, 1993.
  • Hubner, WD., Lande S., Podzuweit H.: “Hypericum treatment of mild depression with somatic symptoms”, J Geriatr Psychiatry Neurol, 7 Suppl 1:S12-14, 1994.
  • Johne A., Brochmoller J., Bauer S., Maurer A., Langheinrich, Roots I. (1999) “Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum)”, Clin Pharm Ther, Vol.66, No 4, 338-45, 1999.
  • Josey E.S., Tackett R.L.: (1999) “St. John's wort: a new alternative fordepression”, Int J Clin Pharmacol Ther, 37(3):111-9, 1999.
  • Kall M.A.: “Dietary effect on mixed function, P450 1A2 activity assayed by estimation of caffeine metabolism in man”, Hum Exp Toxicol, Vol. 14 (10), 801-7, 1995.
  • Kasper S., Schulz V.: Wien Med Wochenschr, 149(8-10):191-6, 1999.
  • Kleber E., Obry T., Hippeli S. et al.: “Biochemical activities of extracts from Hypericum perforatum L. 1st Communication: inhibition of dopamine-beta-hydroxylase”, Arzneimittelforschung, 49(2):106-9, 1999.
  • Laakmann G. et al.: “St John's Wort in mild to moderate depression”, J Pharmacopsychiat; 31(suppl 1): 34-8, 1998.
  • Lantz M.S., Buchalter E., Giambanco V.: “St. John's wort and antidepressant drug interactions in the elderly”, J Geriatr Psych Neurol, 12, 7-10, 1999.
  • Lavie G., Mazur Y., Lavie D., Meruelo D.: “The chemical and biological properties of hypericin - a compound with a broad spectrum of biological activities”, Medicinal Research Review, 15:111-9, 1995.
  • Lenard J., Rabson A., Vanderoef R.: “Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: Inhibition of fusion and syncitia formation”, Proc Natl Acad Sci, 90:158-62, 1993.
  • Lenoir S., Degenring F.H., Saller R.: “A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of Hypericum perforatum L.”, Phytomed, 6(3):141-6, 1999.
  • Leuschner J.: “Preclinical toxicological profile of Hypericum extract LI160”, Phytomed Int J Phytother Phytopharmacol, 3 Suppl. 1: 104, 1996/7.
  • Linde K., Ramirez G., Mulrow CD., Pauls A., Weidenhammer W., Melchart D.: “St John's Wort for depression - An overview and meta-analysis of randomised clinical trials”, BMJ, 313(7052):253-8, 1996.
  • MacAuliffe et al. : “A phase I dose escalation study of sinthetic hypericin in HIV infected patients /ACTG 150)”, Natl Conf Hum Retroviruses Relat Infect (1st), Washington, Abstract 57012-6:159, 1993.
  • Marcowitz J.S., DeVane C.L., Carson S.W., Nahas Z., Bouton D.W., Chike-Harris K., Leung J.W.W., Risch S.C.: Journal of European College of Neuropsychopharmacol, Vol 9, Supp. 5, p. S367.
  • Martinez B., Kasper S., Ruhrmann S., Moller HJ.: “Hypericum in the treatment of seasonal affective disorders, J Geriatr Psychiatry Neurol, 7 Suppl 1:S29-33, 1994.
  • McIntyre M.: “Alternative Licensing for Herbal Medicine-Like Products in the European Union”, J Altern Complement Med, 5: 110-3, 1999.
  • Melzer R., Fricke U., Holzl J.: “Vasoactive properties of procyanidins from Hypericum perforatum L. in isolated porcine coronary arteries”, Arzneimittelforschung, 41(5):481-3, 1991.
  • Muller W.E., Singer A., Wonnemann M. et al.: “Hyperforin represents the neurotransmitter re-uptake inhibiting constituent of Hypericum extract”, Pharmacopsych, 31 Suppl 1:16-21, 1998.
  • Muller WE. and Rossol R.: “Effects of hypericum extracts on the suppression of serotonine receptors”, J Geriatric Psychiatry Neurology, 7: S63-4, 1994.
  • Nahrstedt and Butterweck: “Biologically active and other constituents”, J Pharmacopsychiat, 30: 129-34, 1997.
  • Nebel A., Schneider B.J., Baker R., Kroll D.: “Potential metabolic reaction between St. John's Wort and theophylline”, Annals of Pharmacother, Vol. 33, 502, 1999.
  • Negrash et al.: “Comparative study of chemotharapeutic and pharmacological properties of antimicrobial preparations from common St John's Wort”, Fitontsidy Mater Seveshch, 6th meeting:198-200, 1972.
  • Obermeier M.T., White R.E., Yang C.S.: “Effects of bioflavonoids on hepatic P450 activities”, Xenobiotica, 25, 575-84, 1995.
  • Okpanyi S.N., Lidza H. et al.: “Genotoxicity of standardised Hypericum extract”, Arzneimittelforschung, 40(8):851-5, 1990.
  • Panossian J., Gabrielian E., Manvelian V., Jurcic K., Wagner H.: “Immunosoppressive effects of hypericin on stimulated human leucocytes: inhibition of the arachidonic acid release, leukotriene B4 and interleukin-1 production and activation of nitric oxide formation”, Phytomedicine, 3:19-28, 1996.
  • Payne: citato in HIV and AIDS treatment directory, Hypericin NAM Publ London, 1995.
  • Perovic S. and Muller W.E.: “Pharmacological profile of Hypericum extract. Effect on serotonin uptake by postsynaptic receptors”, Arzneimittelforschung, 45(11):1145-8, 1995.
  • Piscitelli S.C., Burstein A.H., Chaitt D., Alfaro R.M., Falioon J.: “Indinavir concentrations and St. John's wort”, Lancet, Vol. 355, Feb 12, 54, 2000.
  • Pitisuttithum P., Migasena S., Suntharasamei P., Sutthan R., Perathamanond P., Wasi C., Shikan U., Peeters BP., Tobia: “Hypericin: Safety and antiretroviral activity in Thai HIV positive volunteers”, XI Int Conf AIDS, Vancouver, 1:285, 1996 (abstract Tu B2121).
  • Poginsky B., Westindorf J. et al.: “Johaniskraut (Hypericum perforatum L.). Genotoxizitat bedingt durch den Quercertingehalt”, Dtsch Apoth Ztg, 128:1464-6, 1988.
  • Priest and Priest: Herbal Medication, London: L N Fowler, 1982.
  • Qin-Ying Yue, Bergquist C., Gerden B.: “The safety of St. John's Wort”, Lancet, Vol. 355, 576, 2000.
  • Raffa R.B.: “Screen of receptor and uptake-site activity of hypericin component of St. John's Wort reveals sigma receptor binding”, Life Sci, 62(16):PL265-70, 1998.
  • Rao et al.: “Calendula and Hypericum: Two homeopatic drugs promoting wound-healing in rats”, Fitoterapia, 6:508-10, 1991.
  • Rev J.M., Walter G.: “Hypericum perforatum L.(St. John's wort) in depression: pest or blessing?”, Med J Aust, 169, 583-6, 1998.
  • Roberts J.: “Ozone depletion - ocular effect of enhanced UVB”, Abstract, 27th Annual Meeting of the American Society for Photobiology, Washington D.C. USA, 1998.
  • Roberts J.E., Wang R.H., Tan I.P., Datillo M. and Chignell F.: “Hypericin (active ingredient in St. John's wort) photooxidation of lens proteins”, Photochem Photobiol, Vol. 69 (6), 1999.
  • Roby A., Kantor B.A., Anderson G.D., Burstein A.H.: “St. John's wort impact on CYP3A4 activity”, NCDEV, Poster no. 129, 1999.
  • Ruschitzka F., Meler P.J., Turina M., Luscher T.F., Noli G.: “Acute heart transplant rejection due to St. John's wort”, Lancet, Vol. 355, 548, 2000.
  • Saljic J.: “Ointment for the treatment of burns”, Ger Offen, 2:406-52, 1975.
  • Sandberg SL. et al.: “Leaf-tying by tortricid larvae as an adaptation for feeding on phototoxic Hypericum perforatum, J Chem Ecology, 15(3): 875-86, 1989.
  • Schempp C.M., Winghofer B., Langheinrich M., Schopf E., Simon J.C.: “Hypericin levels in human serum and interstitial skin blister fluid after oral single-dose and steady-state administration of Hypericum perforatum L. extract”, Skin Pharmacol Appl Skin Physiol, 12(5):299-304, 1999.
  • Schilling W.: “Die Gattung Hypericum unter besonderer Berucksichtigung von Hypericum perforatum L.”, Praparative Pharmazie 5(8):125-34, 1969.
  • Schimmer O., Haefele R., Kruger A.: “The mutagenic potencies of plant extracts containing quercertin in Salmonella typhimuriom TA98 and TA100”, Mutat Res, 206:201-8, 1988.
  • Schmidt U., Sommer H.: “[St. John's wort extract in the ambulatory therapy of depression. Attention and reaction ability are preserved.] Johanniskraut-Extrakt zur ambulanten Therapie der Depression. Aufmerksamkeit und Reaktionsvermogen bleiben erhalten“, Fortschr Med, 111(19): 339-42, 1993.
  • Schulz H., Jobert M.: “Effects of hypericum extract on the sleep EEG in older volunteers”, J Geriatr Psychiatry Neurol, 7 Suppl 1:S39-43, 1994.
  • Simmen U., Burkard W., Berger K., et al.: “Extracts and constituents of Hypericum perforatum L. inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system”, J Recept Signal Transduct Res, 19(1-4):59-74, 1999.
  • Singer A., Wonnemann M., Muller W.E.: “Hyperforin, a major antidepressant constituent of St. John's wort, inhibits serotonin uptake by elevating free intracellular Na+1”, J Pharmacol Exp Ther, 290(3):1363-8, 1999.
  • Smith RS.: “The macrophage theory of depression”, Med Hypotheses, 35:298-306, 1991.
  • Soldner A., Christians U., Susanto M., Wacher V.J., Silverman J.A., Benet L.Z.: “Grapefruit juice activates P-glycoprotein-mediated drug transport”, Pharm Res, 16, 478-85, 1999.
  • Staffeldt B. et al.: “Pharmacokinetics of hypericin and pseudohypericin after oral intake of the Hypericum perforatum extract LI 160 in healthy volunteers”, J Geriatr Psychiatry Neurol, 7 Suppl:S47-53, 1994.
  • Steinbeck Klose A., Wernet P.: “Successful long term treatment over 40 months of HIV patients with intravenous hypericin”, IX Int Conf AIDS, Berlin, (Jun 6-11), 9(1): 470, 1993 (abstract no. PO-B26-2012).
  • Suzuki O., Katsumata Y., Oya M., Bladt S., Wagner H.: “Inibition of monoamine oxidase by hypericin, Planta Medica, 50:272-4, 1984.
  • Takahashi I, Nakanishi S, Kobayashi E, Nakano H, Suzuki K, Tamaoki T “Hypericin and pseudohypericin specifically inhibit protein kinase C: Possible relation to their antiretroviral activity.” Biochem Biophys Res Commun 165(3):1207-1212 . 1989
  • Thiede H.M., Walper A.: “Inhibition of MAO and COMT by Hypericum extracts and hypericin”, J Geriatr Psych Neurol, 7 Suppl 1:S54-6, 1994.
  • Thiele B., Brink I., Ploch M.: “Modulation of cytokine expression by hypericum extract”, J Geriatr Psychiatry Neurol, 7 Suppl 1:S60-2, 1994.
  • Thomas C., MacGill Miller GC., Pardini RS.: “Photoactivation of hypericin generates singlet oxygen in mitochondria and inhibits succinoxidase”, Photochem Photobiol, 55:47-53, 1992b.
  • Thomas C., MacGill RS., Neill P., Pardini RS.: “The in vitro and in vivo photoindiced antineoplastic activity of hypericin (meeting abstract)”, Proc Annu Meet Am Assoc Cancer Res, 33:A2989, 1992a.
  • Thomas-Bradley CJ.: “Hypericin as a potential photosensitizer in photodynamic therapy of cancer”, Diss Abstr Int [B] 52(9):4715, 1992.
  • Trinidade E.: “Selective serotonin re-uptake inhibitors differ from tricyclic antidepressants”, Evidence Based Medicine, May/June: 86-7, 1998.
  • Vandebogaerde A., de Witte P.: “Antineoplastic properties of photosensitized hypericin (Meeting abstract)”, Anticancer Res 15(5A): 1757-8, 1995.
  • Vandenbogaerde A. L., Els M., Vantieghem A.M. et al.: “Cytotoxicity and antiproliferative effect of hypericin and derivatives after photosensitization”, Photochem Photobiol, 67: 119, 1988.
  • Vandenbogaerde A.L. et al.: “Photocytotoxic effect of pseudohypericin versus hypericin”, J Photochem Photobiol, B 45(2-3):87-94, 1998.
  • Vansover A. et al.: “HIV-1 virus load in the serum of AIDS patients undergoing long term therapy with hypericin”, XI Int Conf AIDS, Vancouver, 1:120, 1996 (abstract Mo B 1377).
  • Vistisen K., Loft S., Poulson H.E.: “Cytochrome P450 1A2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise”, Adv Exp Med Biol, 283, 407-11, 1991.
  • Vitiello, B.: “Hypericum perforatum L. Extracts as potential antidepressants”, J Pharm Pharmacol, 51: 513-517, 1999.
  • Vonsover A., Steinbeck K.A., Rudich et al.: “HIV-1 virus load in the serum of AIDS patients undergoing long term therapy with hypericin”, Int Conf AIDS (Jul 7-12) 11(1):120, 1996 (abstract no. Mo.B.1377).
  • Vorbach EU., Hubner WD., Arnoldt KH.: “Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine. Randomized double-blind study with 135 outpatients”, J Geriatr Psychiatry Neurol, 7 Suppl 1:S19-23, 1994.
  • Weiss, R.E.: Lehrbuch der Phytotherapie, 7th Ed. pp. 366-9, Hippokrates Verlag. Stuttgart, Germany, 1990.
  • Wheatley D.: Lancet, Vol. 355, 576, 2000.
  • Wichtl, M.: Herbal Drugs and Phytopharmaceuticals, p. 274, CRC Press Boca Raton, Ann Harbour, London, Tokyo, 1994.
  • Witte B., Harrer G., Kaptan T., Podzuweit H., Schmidt U.: “[Treatment of depressive symptoms with a high concentration hypericum preparation. A multicenter placebo-controlled double-blind study] Behandlung depressiver Verstimmungen mit einem hochkonzentrierten Hypericumpraparat“, Fortschr Med, 113(28):404-8, 1995.
  • Woelk H., Burkard G., Grunwald J.: “Benefits and risks of the hypericum extract LI 160: Drug monitoring study with 3250 patients”, J Geriatr Psychiatry Neurol, 7 Suppl 1:S34-8, 1994.
  • Yip L., Hudson JB., Kowalik EG., Zalkow LH., Towers GHN.: “Antiviral activity of a derivative of the photosensitive compound hypericin”, Phytomedicine, 3:185-90, 1996.
Tue, 17 May 2005 11:18:48 +0200


Licenza Creative Commons
Il database InfoErbe
è pubblicato con
Licenza Creative Commons

Marco Valussi
Luciano Posani

Copyright 2000 - 2005 Miro International Pty Ltd. All rights reserved. Mambo is Free Software released under the GNU/GPL License.